What is it about?
Study tests chronic effects of beta-secretase inhibition on the magnitude of microbleeds in the brains of mice engineered to develop amyloid plaques characteristic of Alzheimer's disease. Microbleeds or microhemmorhages are commonly observe in AD patients and experimental therapies that alter the status of amyloid plaques can elevate microbleeds.
Featured Image
Why is it important?
Study informed on the safety risks for beta-secretase inhibition to cause microbleeds in AD patients treated with the beta-secretase inhibitor verubecestat
Perspectives
This was a logistically and technically very challenging and in the end provided robust data on safety and efficacy for suppressing plaque load in a relevant model of plaque pathology. We also described unexpected changes parenchymal vs. vascular amyloid load.
Matthew Kennedy
Merck and Co Inc
Read the Original
This page is a summary of: Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage, Journal of Alzheimer s Disease, August 2017, IOS Press,
DOI: 10.3233/jad-170056.
You can read the full text:
Contributors
The following have contributed to this page
